Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and Sodium-glucose cotransporter 2 (SGLT-2) inhibitors are widely used for Type 2 diabetes and weight management but may adversely affect skin quality, resulting in dermal thinning, decreased elasticity, and accelerated aging—a phenomenon referred to as “GLP-1 Face.”
Do you have an idea for a study but don’t where to start or how to finance it? The Aesthetic Foundation has awarded over $3 Million dollars to aesthetic surgery research since it was founded in 1993.
Dr. Tracy Pfeifer highlights key developments for The Aesthetic Society, including the new impact factor for Aesthetic Surgery Journal, evolving needs across generations of surgeons, plans for The Aesthetic MEET 2026, upcoming participation at ISAPS in Singapore, and an important cybersecurity alert for members.
My theme for this year as President of The Aesthetic Foundation is “to make a difference”. The Foundation is in a unique position as the research, education, and charitable arm of The Aesthetic Society to achieve that goal.